TY - JOUR
T1 - Infliximab-Induced Aseptic Meningitis in a Patient with Crohnʼs Disease
AU - Junga, Zachary
AU - Theeler, Brett
AU - Singla, Manish
PY - 2018
Y1 - 2018
N2 - Infliximab is an anti-tumor necrosis factor a (TNFa) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.
AB - Infliximab is an anti-tumor necrosis factor a (TNFa) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.
UR - https://www.mendeley.com/catalogue/abb3071d-6b7f-3d02-9bbc-a28dd0634a6c/
U2 - 10.14309/crj.2018.48
DO - 10.14309/crj.2018.48
M3 - Article
SN - 2326-3253
VL - 5
SP - e48
JO - ACG case reports journal
JF - ACG case reports journal
IS - 1
ER -